Go back to the Europarl portal

Choisissez la langue de votre document :

  • bg - български
  • es - español
  • cs - čeština
  • da - dansk
  • de - Deutsch
  • et - eesti keel
  • el - ελληνικά
  • en - English (Selected)
  • fr - français
  • ga - Gaeilge
  • hr - hrvatski
  • it - italiano
  • lv - latviešu valoda
  • lt - lietuvių kalba
  • hu - magyar
  • mt - Malti
  • nl - Nederlands
  • pl - polski
  • pt - português
  • ro - română
  • sk - slovenčina
  • sl - slovenščina
  • fi - suomi
  • sv - svenska
Parliamentary questions
PDF 6kWORD 18k
20 October 2017
E-005446/2017(ASW)
Answer given by Mr Andriukaitis on behalf of the Commission
Question reference: E-005446/2017

The organisation of health systems and delivery of care is the responsibility of Member States. The Commission can therefore not harmonise national legislation on access to medicines. However, the Commission recognises the importance of timely access to innovative medicines for patients and facilitates EU cooperation in different areas concerning access to medicines.

One of the initiatives is Health Technology Assessment (HTA), which assesses the added value of given health technology over and above existing ones, helping Member States to allocate national resources to effective health interventions. HTA can speed up process of market access and thus improve patient access to innovative technologies The Commission is currently preparing an initiative on strengthening EU cooperation on HTA.

The Commission supports improved exchange of information among Member States and promotes voluntary cooperation for example through the Network of competent authorities responsible for pricing and reimbursement(1), and through a European medicine price data base(2). It also supports an Organisation for Economic Cooperation and Development project on Sustainable Access to Innovative Therapies(3).

The Commission has mandated the Expert Panel on Effective Ways of Investing in Health(4) to develop an Opinion on ‘Innovative payment models for high-cost innovative medicines’, which would assist Member States to develop policies on cost-effective use of medicines.

(1)Known as CAPR.
(2)http://ec.europa.eu/chafea/documents/health/euripid-leaflet_en.pdf
(3)http://www.oecd.org/els/health-systems/pharmaceuticals.htm
(4)http://ec.europa.eu/health/expert_panel/

Legal notice